PRESS RELEASES
Archives
November 14, 2012 - Fast Relief of Migraine Pain Achieved with New OptiNose Migraine Treatment, Phase III Clinical Data Show Headache Relief Begins as Early as 15 Minutes After Administration of New OptiNose Migraine Treatment
November 8, 2012 - OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
October 18, 2012 - Study Shows OptiNose Bi-Directional™ Nasal Technology Reaches Target Areas of the Nasal Cavity Much More Effectively Than Traditional Nasal Spray
October 2, 2012 - Popular Migraine Medicine Quickly Absorbed When Delivered With Novel Breath Powered OptiNose Bi-Directional™ Nasal Technology, New Comparative Data Demonstrates
February 14, 2012 - OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
February 2, 2012 - OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology
August 1, 2011 - OptiNose Announces Additional Leadership Team Members
May 23, 2011 - OptiNose Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application
November 3, 2010 - OptiNose Receives Nearly $489,000 Grant Award Under U.S. Government Qualifying Therapeutic Discovery Project Program
October 28, 2010 - Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose’s Novel Drug Delivery Technology